Abstract
AbstractHTE 3.0 aims to support clinicians in the detection of patients with dyslipidemia, especially patients with familial hypercholesterolemia (FH), and in the recommendation of personalized lipid‐lowering treatments. The core of HTE 3.0 is a clinical decision support system in which several knowledge‐based systems are serialized: patient detection, therapeutic target setting, personalized treatment assessment, and treatment combination and prioritization, according to different criteria. The experimental evaluation of HTE 3.0 shows that the use of HTE 3.0 would mean increasing the capacity to detect FH by 5.7 times compared with usual clinical practice. Regarding the lipid‐lowering treatment, a comparison of 18 cases among seven lipidologists shows that the differences between treatments provided by HTE 3.0 and human lipidologists are smaller than the differences between human experts.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have